Type 2 Diabetes Trial, Recruiting NCT04791371 Sponsor: University of Colorado, Denver Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT04791371
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who do less than 1 hour of physical activity per week (considered sedentary)
  • People with a BMI between 25 and 40
  • Both men and women, with or without type 2 diabetes, may be considered

Who may not be able to join:

  • People with a diagnosed heart or cardiovascular disease
  • People with uncontrolled high blood pressure (systolic above 150 or diastolic above 110)
  • People with obstructive pulmonary disease or asthma
  • People with peripheral neuropathy (nerve damage, usually in the hands or feet)
  • People with a physical condition that would limit their ability to exercise
  • People currently taking beta blockers, calcium channel blockers, insulin, or a class of diabetes medications called Thiazolidinediones (TZDs)
  • People who have smoked within the last year, or who currently use tobacco products
  • People with anaemia (low red blood cell levels)
  • People without diabetes whose HbA1c (a blood sugar measure) is above 5.7, or people with type 2 diabetes whose HbA1c is above 9 (confirm with trial site)
  • People who are pregnant, nursing, or on hormonal therapy (other than contraceptives)
  • Women who are peri-menopausal or post-menopausal
  • People with type 1 diabetes
  • People with liver or kidney disease

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 303-724-1338

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
17 June 2022
Est. completion
15 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in peak oxygen consumption (VO2); Change in insulin sensitivity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov